April 2026: News
Download PDF
Ceria Completes Initial Phase of Strategic Plan in Puerto Rico
Establishing the island as the primary site for company operations
San Juan, Puerto Rico – April 29, 2026 – Ceria Therapeutics, Inc. (Ceria) announces the execution of its decree under Puerto Rico’s Act-60 (the Puerto Rico Incentives Code), completing the initial phase of the company’s long-term strategic plan and establishing Puerto Rico as the home for Ceria’s operations and growth.
The decree, the result of an extensive process of planning, engagement, and collaboration with the Government of Puerto Rico, affirms Ceria’s commitment to build its future in partnership with the island — its people, its institutions, and its world-class biopharmaceutical ecosystem.
“Puerto Rico has an extraordinary legacy in pharmaceutical manufacturing and innovation, a highly skilled workforce, and a community that takes pride in the medicines it helps bring to patients worldwide. Ceria is proud to call Puerto Rico home.”
David Jackson, PhD, CEO
Why Puerto Rico?
Ceria has established operations in Puerto Rico to join the island’s robust biopharmaceutical ecosystem and to leverage the island’s extensive resources and capabilities for medical innovators.
A legacy of pharmaceutical excellence
For more than seventy years, Puerto Rico has been a leader of U.S. pharmaceutical manufacturing, offering deep technical expertise, integrated supply chain and distribution capabilities, and proven operational excellence that few can match.
A highly skilled, mission-driven workforce
Puerto Rico’s R&D and manufacturing professionals bring talent, experience, and a deep commitment to the patients their work ultimately serves.
A robust R&D ecosystem
Through its universities and research institutions, Puerto Rico provides the connective tissue needed to innovate, develop, and create the next generation of drugs.
A committed government partner
The Government of Puerto Rico continues to demonstrate a long-term commitment to fostering innovation, supporting R&D, and investing in the biopharmaceutical and other industries with the Act-60 incentives program.
A shared vision for growth
Ceria and Puerto Rico share a vision of establishing an enduring legacy for the island and global marketplace by investing in the people, research, and infrastructure that benefit patients, communities, and the broader economy.
About Act-60
Puerto Rico’s Act-60, enacted in 2019, is the third legislative act codifying incentives to attract and retain investment, business activity, and talent on the island. Act-60 provides support for long-term operations and innovation on island and to attract new companies and talent to Puerto Rico.
About Ceria Therapeutics, Inc.
Ceria is a pre-clinical biopharmaceutical development company with facilities in Tucson AZ and San Juan PR. The company is advancing a pipeline of RNA- interference (RNAi) drug products using a next-generation RNA to target severe inflammatory conditions in the critical care, GI, and wound care markets.
Ceria conducts in-house R&D and manufacturing of our novel RNAi biopharmaceutical pipeline. US-manufactured synthetic RNAi for R&D and manufacturing are in high demand and will be commercialized to other biopharmaceutical companies.
Ceria currently has six therapeutic assets in active development across its expanding, next-generation RNAi-based drug discovery and development pipeline. Two Investigational New Drug (IND) applications are projected to be submitted for advanced wound care and critical care assets in 2026 to initiate clinical trials. Ceria’s research is in-part supported by the US Department of Defense and National Institutes of Health funded programs for therapeutic advancement.
Ceria Therapeutics, Inc.
info@ceriatx.com